enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Price Target of $11.05

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been given an average rating of “Hold” by the fourteen research firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $11.05.

A number of brokerages have recently commented on ENGN. Wall Street Zen raised shares of enGene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Jefferies Financial Group upgraded shares of enGene to a “strong-buy” rating in a research report on Tuesday, October 13th. HC Wainwright reaffirmed a “buy” rating on shares of enGene in a report on Friday, October 16th. Citizens Jmp reiterated a “market perform” rating on shares of enGene in a research report on Wednesday, September 9th. Finally, Weiss Ratings cut enGene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 30th.

Hedge Funds Weigh In On enGene

Hedge funds and other institutional investors have recently modified their holdings of the company. Siren L.L.C. increased its position in shares of enGene by 57.5% during the 1st quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock valued at $35,774,000 after purchasing an additional 1,916,895 shares during the last quarter. SR One Capital Management LP purchased a new position in shares of enGene during the 2nd quarter valued at about $1,293,607. Eversept Partners LP lifted its position in enGene by 12.0% in the 1st quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock worth $3,477,000 after buying an additional 54,708 shares during the last quarter. Monashee Investment Management LLC lifted its position in enGene by 8.5% in the 1st quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock worth $2,179,000 after buying an additional 25,000 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in enGene by 651.1% in the first quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock worth $1,063,000 after buying an additional 135,318 shares in the last quarter. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Price Performance

Shares of NASDAQ ENGN opened at $1.75 on Friday. enGene has a 12 month low of $1.40 and a 12 month high of $12.25. The company has a current ratio of 10.21, a quick ratio of 10.21 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $117.28 million, a price-to-earnings ratio of -0.85 and a beta of -0.24. The business has a 50-day moving average of $1.78 and a 200-day moving average of $4.20.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04). Sell-side analysts expect that enGene will post -1.82 earnings per share for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.